Lixte Accumulated Other Comprehensive Income from 2010 to 2025
| LIXT Stock | USD 1.19 0.11 8.46% |
Accumulated Other Comprehensive Income | First Reported 2006-06-30 | Previous Quarter (225.00) | Current Value (225.00) | Quarterly Volatility 260.78408246 |
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 19.6 K, Other Operating Expenses of 6.1 M or EBITDA of 3.9 K, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 1.06. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
Lixte | Accumulated Other Comprehensive Income |
Latest Lixte Biotechnology's Accumulated Other Comprehensive Income Growth Pattern
Below is the plot of the Accumulated Other Comprehensive Income of Lixte Biotechnology Holdings over the last few years. It is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. Lixte Biotechnology's Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Accumulated Other Comprehensive Income | 10 Years Trend |
|
Accumulated Other Comprehensive Income |
| Timeline |
Lixte Accumulated Other Comprehensive Income Regression Statistics
| Arithmetic Mean | (38.74) | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | (215.57) | |
| Mean Deviation | 62.96 | |
| Median | 0.00 | |
| Standard Deviation | 83.52 | |
| Sample Variance | 6,975 | |
| Range | 225 | |
| R-Value | (0.67) | |
| Mean Square Error | 4,118 | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (11.75) | |
| Total Sum of Squares | 104,623 |
Lixte Accumulated Other Comprehensive Income History
About Lixte Biotechnology Financial Statements
Lixte Biotechnology shareholders use historical fundamental indicators, such as Accumulated Other Comprehensive Income, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | (202.50) | (192.37) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.